|Boehringer Ingelheim||Global Head, CNS BD and Licensing||Germany|
Assessing the opportunity in licensing early-stage projects
Global Head, Business Development & Licensing CNS at Boehringer Ingelheim
Dr. Mendla received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship in Neuropathology at the University of Heidelberg.
Since joining Boehringer Ingelheim (BI) in 1985, he has held several positions in Research and
Development within the corporation. Before joining BI’s global Business Development and Licensing organization, Dr. Mendla was director of the company’s neurodegenerative diseases research group.
Dr. Mendla currently acts as Global Head, Business Development & Licensing CNS at Boehringer Ingelheim. He is member of BI’s CNS Therapeutic Area Leadership Team and heads up the cross-functional CNS Licensing Advisory Team which is responsible for BI’s global partnering and licensing activities in the therapeutic area CNS Diseases.
The strategic partnering focus of Dr. Mendla and his team is on compounds and novel therapeutic approaches for the treatment of neuropsychiatric diseases (including Alzheimer’s disease, schizophrenia and depression).